BLFS · Biolife Solutions Inc
$35.07
-0.16 (-0.45%)
At close · Aug 14
Market Cap
$1.72B
Shares
48.91M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$35.07
Open$35.17
Day$34.81–35.22
52W close$18.15–35.23
Avg vol 30d1.2M
Short int4.5M · 9.3% float · 2.1d
Short vol36%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+42%
above
Price vs 50-day avg
+19%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+53%
trailing
YTD return
+45%
this year
Relative strength
+40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$28.1M over 90 days · 100% sells
Short interest
Rising
9.29% of float · ▲ +59.1% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+29%
Y/Y
Gross margin
65%
contracting
EPS growth
+77%
Y/Y
Free cash flow
$10.6M
Valuation
P/E 30.2
below peers
Balance sheet
$28.0M
net cash
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Revenue
· 2026 financial guidance
$112.5M – $115M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total 2025 revenue
· full-year 2025
$95M – $96M
Cell Processing platform revenue
· full-year 2025
$93M – $94M
Guided vs delivered
· last 2 settled
Total 2025 revenue
full-year 2025
guided $95M – $96M
$96.21M
Beat +0.7%
Total revenue
2024
guided $95.5M – $100M
$74.65M
Miss −23.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+42%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$28.1M over 90 days · 100% sells
Short interest
Rising
9.29% of float · ▲ +59.1% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $18
Now $35 · 99%
Range high $35
vs 200-day avg +42%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $13.5M | six months ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 24% | six months ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 65% | six months ended June 30, 2026 | — |
| Adjusted net income non-GAAP | $6.3M | six months ended June 30, 2026 | — |
| Adjusted operating income non-GAAP | $4.1M | six months ended June 30, 2026 | — |
| Biopreservation media embedded in unique commercial CGTs | 18 | as of June 30, 2026 | — |
| Biopreservation media market share in U.S. commercially sponsored clinical trials | 70% | Q2 2026 | — |
| Biopreservation media utilized in ongoing commercially sponsored CGT clinical trials in the U.S. | 250 | Q2 2026 | — |
| Clinical trials using CellSeal vials and hPL products | 35 | Q2 2026 | — |
| Phase III trial market share of biopreservation media | 80% | Q2 2026 | — |
| Phase III trials utilizing biopreservation media | 30 | Q2 2026 | — |
| ongoing commercially sponsored clinical trials in the U.S. utilizing biopreservation media | 250 | as of Q1 2026 | — |
| Biopreservation media embedded in unique commercial CGT products | 16 | as of December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLFS
this stock
Biolife Solutions Inc
|
$1.72B | +45.0% | +28.9% | 30.2 | 9.3% |
|
ISRG
Intuitive Surgical Inc
|
$139.37B | -30.3% | +20.5% | 45.3 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.99B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.89B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLFS | +1.2% | +20.3% | +53.3% | +12.1% | +45.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.8% | +15.9% | +39.5% | +8.2% | +31.2% |